News | Medicines Discovery Catapult

We can arrange media interviews and tours of our laboratory and facilities. Spokespeople, including our CEO, Chris Molloy, are available to comment on our unique approach to supporting SMEs and the discovery of new medicines.

We can also provide expert opinion and analysis on the UK government’s Industrial Strategy, the role of the NHS, SMEs, pharma and the importance of patient data in drug discovery. You can find out more about our work in the State of the Discovery Nation report.

For more information please email media@md.catapult.org.uk.

Signup to our media list to be kept up-to-date with our work and commentary and opinion on key news stories.

Medicines Discovery Catapult welcomes UK Government’s long-term investment in life sciences innovation

In response to the UK Government’s Budget 2020 , Chris Molloy, CEO of the Medicines Discovery Catapult said: “Today’s budget announced £200M in funding directly targeted at the life sciences, and dramatically increased scientific research funding, providing more breakthroughs that we can help our sector turn into commercial products. Medicines Discovery Catapult is testament to the Government’s broad […]

Medicines Discovery Catapult Nurture Next Generation Drug Discovery Researchers

Medicines Discovery Catapult (MDC) have welcomed a cohort of MRC-funded PhD students as part of a training, talent and skills agenda to help develop the next generation of drug discovery researchers. Charlotte Criscuolo, University of Manchester; Rebecca Kelly, University of Liverpool; Michael Eyres, University of Oxford; and Tim Muntslag, University of Southampton have joined MDC […]

MDC celebrates International Day of Women and Girls in Science

To mark International Day of Women and Girls in Science, we are celebrating by highlighting some of the MDC women who play a vital part in making drug discovery happen. We asked them two questions: 1. What is the best thing about working in science? 2. What career advice would you give to your younger […]

Dr Martin Main Guest Editor of SLAS Discovery Special February Issue: Advances in Cellular Target Engagement and Target Deconvolution

The February special issue of SLAS Discovery, ‘Advances in Cellular Target Engagement and Target Deconvolution,’ features 11 articles focused on multiple aspects and technologies of cellular target engagement. Special issue editors Martin Main, Ph.D., Head of Molecular Technologies, Medicines Discovery Catapult and Andrew Zhang, Ph.D., (AstraZeneca, USA) selected articles that span a variety of relevant […]

Catapult Network welcomes UK Government’s announcement of support for science, research and innovation

In response to the UK Government’s announcement on investment in science, research and innovation in the UK, and the upcoming Place Strategy for UK research and development, Andrew Jamieson, CEO of the Offshore Renewable Energy Catapult and Chair of the Catapult Network, said: “The Catapult Network welcomes the announcement of the Government’s commitment to boosting […]

Medicines Discovery Catapult, use MY data and Incisive Health publish ‘Issue with Tissue’ report

Today (22nd January 2020) Medicines Discovery Catapult, alongside Incisive Health and use MY data published ‘The Issue with Tissue’, a report that brings together key figures from across the patient, clinical and research community to consider how more tissue samples could be used, more effectively. About 1 million patients have consented to their samples being […]

Hearing Medicines Discovery Syndicate launches to fast-track the development of hearing therapeutics

Today (9th January 2020), the charity Action on Hearing Loss and Medicines Discovery Catapult announce the launch of the Hearing Medicines Discovery Syndicate, a unique collaboration to accelerate the much-needed development of treatments for hearing loss and tinnitus. Hearing loss affects almost half a billion people globally, with almost 12 million people in the UK […]

Psychiatry Consortium brings Charles River Laboratories and Evotec on board

World-leading drug discovery organisations Charles River Laboratories and Evotec join the Psychiatry Consortium as drug discovery and development partners. The two organisations bring invaluable expertise and capabilities to the Psychiatry Consortium, significantly enhancing the offering to the research community. The Psychiatry Consortium, managed by Medicines Discovery Catapult, brings together academia, industry, charity and government-funded organisations to develop and […]

LUNAC Therapeutics led project awarded £3.14 million under Innovate UK Biomedical Catalyst programme, to develop next-generation anticoagulant

Today (2nd December 2019) LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk announced that, along with the Medicines Discovery Catapult and the University of Leeds, it has been awarded £3.14M funding under Innovate UK’s Biomedical Catalyst programme. The funding will be […]

Older posts

Newer posts